Back to top

Myriad Genetics Inc: (MYGN)

(Delayed quote from NSDQ) As of Aug 22, 2014 03:59 PM ET

 Add to portfolio

 ZacksTrade Now

$36.51 USD

36.51

-0.78 (-2.09%)

Volume: 902,472

Zacks Rank : 3-Hold [?]     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1 Strong Buy 26.65%
2 Buy 18.84%
3 Hold 10.45%
4 Sell 4.76%
5 Strong Sell 2.56%
S&P 500 10.28%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The way to access to the Zacks Rank

Company Summary

Myriad Genetics, Inc. uses gene-based medicine to develop therapeutic and molecular diagnostic products. They employ a variety of proprietary proteomic technologies to discover disease genes and to understand the role these genes and their related proteins play in the onset and progression of disease. They have integrated these technologies using bioinformatics and robotics systems to conduct their research efforts on a high-throughput basis. This has enabled them to identify numerous proteins as targets for new drugs and molecular diagnostic tests.

General Information

MYRIAD GENETICS

320 WAKARA WAY

SALT LAKE CITY, UT 84108

Phone: 801-584-3600

Fax: 801-584-3640

Web: http://www.myriad.com

Email: sgleason@myriad.com

Industry MED-BIOMED/GENE
Sector Medical
Fiscal Year End June
Last Reported Quarter 6/30/2014
Next EPS Date 11/4/2014

EPS Information

Current Quarter EPS Consensus Estimate 0.41
Current Year EPS Consensus Estimate 1.94
Estimated Long-Term EPS Growth Rate 12.80
Next EPS Report Date 11/4/2014

Price and Volume Information

Zacks Rank
Yesterday's Close 37.29
52 Week High 42.50
52 Week Low 20.02
Beta 1.01
20 Day Moving Average 866,671.19
Target Price Consensus 36.90

MYGN

% Price Change
4 Week -0.16
12 Week 11.28
YTD 78.79
% Price Change Relative to S&P 500
4 Week -0.38
12 Week 7.24
YTD 66.36
Share Information
Shares Outstanding (millions) 74.82
Market Capitalization (millions) 2,790.19
Short Ratio 43.23
Last Split Date 3/26/2009
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio 0.00
Change in Payout Ratio 0.00
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E
P/E (F1) 19.24
Trailing 12 Months 15.41
PEG Ratio 1.50
EPS Growth
vs. Previous Year -9.43%
vs. Previous Quarter -20.00%
   
Sales Growth
vs. Previous Year 8.41%
vs. Previous Quarter 3.19%
   
Price Ratios
Price/Book 3.88
Price/Cash Flow 13.71
Price / Sales 3.59
ROE
6/30/14 26.89
3/31/14 27.78
12/31/13 27.22
ROA
6/30/14 23.75
3/31/14 24.78
12/31/13 24.46
Current Ratio
6/30/14 4.00
3/31/14 4.69
12/31/13 6.74
Quick Ratio
6/30/14 3.70
3/31/14 4.42
12/31/13 6.74
Operating Margin
6/30/14 24.25
3/31/14 25.63
12/31/13 25.48
Net Margin
6/30/14 22.65
3/31/14 24.45
12/31/13 25.48
Pre-Tax Margin
6/30/14 35.71
3/31/14 38.31
12/31/13 39.94
Book Value
6/30/14 9.61
3/31/14 9.90
12/31/13 9.04
Inventory Turnover
6/30/14 10.20
3/31/14 16.78
12/31/13 31.00
Debt-to-Equity
6/30/14 0.00
3/31/14 0.00
12/31/13 0.00
Debt to Capital
6/30/14 0.00
3/31/14 0.00
12/31/13 0.00